Vaxine is pleased to see its latest Covid-19 vaccine Phase 2 trial results complete peer review and be published in the journal “Clinical Microbiology and Infection”, the official journal of the European Society of Clinical Microbiology and Infectious Diseases.

This paper investigates the immunogenicity ad efficacy of Vaxine’s vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2 spike protein combined with Advax-CpG55.2™adjuvant, in seronegative and seropositive populations as primary vaccination.

Link to the published paper: